Brookstone Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Brookstone Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-20,000	Closed	-$56K	–	427
2018 Q4	$56K	Hold	20,000	–	–	﹤0.01%	299
2018 Q3	$82K	Hold	20,000	–	–	0.01%	393
2018 Q2	$104K	Hold	20,000	–	–	0.01%	358
2018 Q1	$110K	Hold	20,000	–	–	0.01%	337
2017 Q4	$163K	Hold	20,000	–	–	0.01%	300
2017 Q3	$209K	Hold	20,000	–	–	0.02%	306
2017 Q2	$221K	Buy	+20,000	New	+$186K	0.02%	281

Other funds holding ENZ

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brookstone Capital Management's ENZ Position: Q1 2019 in Review

Brookstone Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q1 2019, closing a stake of 20,000 shares — an estimated $56K sold.

Brookstone Capital Management first reported a position in ENZ in Q2 2017 and held it in 7 quarters. The position peaked at $221K in Q2 2017. 85 funds tracked by Wall St. Rank hold ENZ as of Q1 2019.

Brookstone Capital Management reported no remaining Enzo Biochem, Inc. position as of Q1 2019 after selling out during the quarter.
Brookstone Capital Management sold 20,000 Enzo Biochem, Inc. shares in Q1 2019, an estimated $56K.
Brookstone Capital Management first reported a position in Enzo Biochem, Inc. in Q2 2017 and held it in 7 quarters.
Brookstone Capital Management's Enzo Biochem, Inc. position peaked at $221K in Q2 2017.
85 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2019.

Based on Brookstone Capital Management's 13F filing for Q1 2019, filed 18 Apr 2019.